Skip to content
Our reporters bring you news and highlights from BIO’s in-person and virtual events.
Given the essential role that intellectual property plays in the development of lifesaving scientific advances, we need to defend and strengthen policy that protects […]
Protect IP protections, BIO 2025 panel urges Read More »
As antimicrobial resistance (AMR) continues to threaten global public health, its impact on cancer patients is a growing, often overlooked crisis. Patients with cancer
BIO 2025: The urgent need to address AMR and cancer Read More »
The exciting new developments we’re seeing in biotechnology must be supported by equally innovative policy, according to Fritz Bittenbender, the new Chair of the
A conversation with Fritz Bittenbender, new BIO Board Chair Read More »
We often talk about the exciting jumps in technology and innovation that improve and save lives. What is less frequently discussed is how regulation
BIO 2025: The innovation race vs. the regulatory pace Read More »
Biotech is a global business, and we’re better for it, said experts at the 2025 Biotechnology Innovation Organization (BIO) International Convention in Boston. International
BIO 2025: The world can’t wait – it needs to collaborate Read More »
Established in 2012, the Pediatric Priority Review (PPRV) program offers a powerful incentive for companies to develop treatments for rare conditions affecting children. Even
BIO 2025: What is the PRV program and why does it matter? Read More »
Health equity should not be considered a parallel initiative, but a central pillar of the biotech industry’s strategy, said experts on Day 3 of
BIO 2025: Health equity as an engine for scalable innovation Read More »
The 2025 Biotechnology Innovation Organization (BIO) International Convention highlighted why we – the biotech industry – do what we do. In one word: patients.
BIO 2025: ‘Behind every data point there is a person’ Read More »
The rare disease patient community is the beating heart of the Biotechnology Innovation Organization’s (BIO) mission. Whether it is driving policy that supports innovation,
BIO 2025: Rare disease patients can’t wait Read More »
The threat to America’s leadership in biotech is a threat to our national security that we need to address now, two members of a
Biotech and national security: ‘Time to act but no time to wait’ Read More »
